Publications by authors named "David A Sandham"

Claim this Profile
G
Genomic crosstalk between carbachol, a muscarinic receptor agonist, and the long-acting β-adrenoceptor agonist, indacaterol, in human airway epithelial cells.
Varuna Jayasinghe, Radhika Joshi, Taruna Joshi, Tamkeen U Paracha, Cora Kooi, David A Sandham

J Pharmacol Exp Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 Synthase.
Gebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, David Orain, Carsten Spanka, David A Sandham

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostaglandin D metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP receptor.
Saskia Carstensen, Christina Gress, Veit J Erpenbeck, Shamsah D Kazani, Jens M Hohlfeld, David A Sandham

Respir Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D Production Are Attenuated by PGD Receptor 2 Antagonism.
Wentao Chen, Jian Luo, Yuan Ye, Ryan Hoyle, Wei Liu, David A Sandham

J Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Darren Le Grand, Martin Gosling, Urs Baettig, Parmjit Bahra, Kamlesh Bala, David A Sandham

J Med Chem· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant, a selective prostaglandin D receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.
Clare Hardman, Wentao Chen, Jian Luo, Paul Batty, Yi-Ling Chen, David A Sandham

J Allergy Clin Immunol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant, a DP receptor antagonist, inhibits eosinophil migration towards mast cells.
Revital Shamri, Gerald Dubois, Veit J Erpenbeck, David Mankuta, David A Sandham

Clin Exp Allergy· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation.
Christian Domingo, Oscar Palomares, David A Sandham, Veit J Erpenbeck, Pablo Altman

Respir Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP Receptor Antagonist for Treatment of Asthma".
David A Sandham, Lucy Barker, Lyndon Brown, Zarin Brown, David Budd

ACS Med Chem Lett· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR.
Si Yan, Duncan E Shaw, Linhong Yang, David A Sandham, Mark P Healy

J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP Receptor Antagonist for Treatment of Asthma.
David A Sandham, Lucy Barker, Lyndon Brown, Zarin Brown, David Budd

ACS Med Chem Lett· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
Callum J Dickson, Viktor Hornak, Camilo Velez-Vega, Daniel J J McKay, John Reilly, David A Sandham

J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
David A Sykes, Michelle E Bradley, Darren M Riddy, Elizabeth Willard, John Reilly, David A Sandham

Mol Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic approaches to site selective deuterium incorporation in a novel CRTh2 receptor antagonist clinical candidate.
David A Sandham, Christopher J Page

J Labelled Comp Radiopharm· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.
David A Sandham, Nicola Arnold, Heinrich Aschauer, Kamlesh Bala, Lucy Barker

Bioorg Med Chem· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
David Beattie, David Beer, Michelle E Bradley, Ian Bruce, Steven J Charlton, David A Sandham

Bioorg Med Chem Lett· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of useful fragments in drug discovery: 2-Amino-5-tert-butylpyridine and its oxidised analogues.
Christopher G Thomson, John Reilly, David A Sandham

Bioorg Med Chem Lett· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
7
7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.
David A Sandham, Claire Adcock, Kamlesh Bala, Lucy Barker, Zarin Brown

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists.
David A Sandham, Clive Aldcroft, Urs Baettig, Lucy Barker, David Beer

Bioorg Med Chem Lett· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
Nichola J Arnold, Ruth Arnold, David Beer, Gurdip Bhalay, Stephen P Collingwood, David A Sandham

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters.
David A Sandham, Lucy Barker, David Beattie, David Beer, Louise Bidlake

Bioorg Med Chem· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on high-temperature amination reactions of aromatic chlorides using discrete palladium-N-heterocyclic carbene (NHC) complexes and in situ palladium/imidazolium salt protocols.
Andrew J McCarroll, David A Sandham, Lisa R Titcomb, Alexandra K de K Lewis, F Geoffrey N Cloke

Mol Divers· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in corticosteroids for the treatment of asthma.
Gurdip Bhalay, David A Sandham

Curr Opin Investig Drugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis